AbbVie in den Nachrichten
Entwicklung biopharmazeutischer Medikamente
Tamtam hat 20 aktuelle Artikel über AbbVie gefunden.
- AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?
- AbbVie options flow shows 4:1 call-to-put ratio as stock rises
- AbbVie price target raised to $320 from $280 at Scotiabank
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
- Should You Buy AbbVie Stock Before Oct. 30?
- AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
- HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
- Better Dividend for Retirees: AbbVie vs. Merck
- Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
- Is AbbVie (ABBV) Still Undervalued On FDA Approval And Fresh Pipeline Data?
- AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
- AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- AbbVie long-term data buoys Rinvoq for vitiligo
- BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie AbbVie?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden